Aug 12, 2020
New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Jun 13, 2020
EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients
Jun 13, 2020
VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
Jun 03, 2020
World Melamine Market Outlook 2020 and Forecasts to 2029 (COVID-19 Adjusted Forecasts) - ResearchAndMarkets.com
May 14, 2020
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)
Mar 23, 2020
AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Jan 24, 2020
2020 Melamine Companies in China - Consecutive Increases of Industrial Output, Imports & Exports, Consumer Consumption & Capital Investment for Over Two Decades - ResearchAndMarkets.com
Jan 15, 2020
Decontaminating pesticide-polluted water using engineered nanomaterial and sunlight
Sep 04, 2019
RDX Announces New Executive Leadership Team
Jul 31, 2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
Apr 10, 2019
RDX Expands Largest Online Marketplace for Oracle to AWS Cloud Migration
Apr 05, 2019
Global Melamine Market Outlook Study (2019-2023) - ResearchAndMarkets.com
Dec 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
Nov 21, 2018
AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Sep 19, 2018
Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting
Jun 18, 2018
Metafrax PJSC Controlled by Seyfeddin Roustamov Approves New Development Strategy up to 2030
Jun 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
Jun 04, 2018
Cantex Pharmaceuticals, Inc. Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
Apr 16, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago
Apr 13, 2018
Global Dicyandiamide Market Estimated to Reach US$ 535 Mn by 2025; Demand for Anti-diabetic Drugs is Increasing Across the Globe: Transparency Market Research